Viatris raises 2026 outlook while targeting $500M peak sales for fast-acting meloxicam (NASDAQ:VTRS)
· seekingalpha.com
Viatris (VTRS) Q2 2026 earnings call: raised guidance, FDA approval catalysts, China growth, Nashik supply risk, and capital plans—read key takeaways.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...